316 related articles for article (PubMed ID: 36327426)
1. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
Johnson ML; Cho BC; Luft A; Alatorre-Alexander J; Geater SL; Laktionov K; Kim SW; Ursol G; Hussein M; Lim FL; Yang CT; Araujo LH; Saito H; Reinmuth N; Shi X; Poole L; Peters S; Garon EB; Mok T;
J Clin Oncol; 2023 Feb; 41(6):1213-1227. PubMed ID: 36327426
[TBL] [Abstract][Full Text] [Related]
2. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
[TBL] [Abstract][Full Text] [Related]
3. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
de Castro G; Rizvi NA; Schmid P; Syrigos K; Martin C; Yamamoto N; Cheng Y; Moiseyenko V; Summers Y; Vynnychenko I; Lee SY; Bryl M; Zer A; Erman M; Timcheva C; Raja R; Naicker K; Scheuring U; Walker J; Mann H; Chand V; Mok T;
J Thorac Oncol; 2023 Jan; 18(1):106-119. PubMed ID: 36240972
[TBL] [Abstract][Full Text] [Related]
4. First-line tremelimumab plus durvalumab and chemotherapy
Liu W; Huo G; Chen P
Front Pharmacol; 2023; 14():1163381. PubMed ID: 37547328
[No Abstract] [Full Text] [Related]
5. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.
Planchard D; Reinmuth N; Orlov S; Fischer JR; Sugawara S; Mandziuk S; Marquez-Medina D; Novello S; Takeda Y; Soo R; Park K; McCleod M; Geater SL; Powell M; May R; Scheuring U; Stockman P; Kowalski D
Ann Oncol; 2020 May; 31(5):609-618. PubMed ID: 32201234
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
8. CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC.
Leighl NB; Laurie SA; Goss GD; Hughes BGM; Stockler M; Tsao MS; Hwang DM; Joubert P; Kulkarni S; Blais N; Joy AA; Mates M; Rana P; Yadav SK; Underhill C; Lee C; Bradbury PA; Hiltz A; Dancey J; Ding K; Vera-Badillo F;
J Thorac Oncol; 2022 Mar; 17(3):434-445. PubMed ID: 34800700
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Schoenfeld JD; Giobbie-Hurder A; Ranasinghe S; Kao KZ; Lako A; Tsuji J; Liu Y; Brennick RC; Gentzler RD; Lee C; Hubbard J; Arnold SM; Abbruzzese JL; Jabbour SK; Uboha NV; Stephans KL; Johnson JM; Park H; Villaruz LC; Sharon E; Streicher H; Ahmed MM; Lyon H; Cibuskis C; Lennon N; Jhaveri A; Yang L; Altreuter J; Gunasti L; Weirather JL; Mak RH; Awad MM; Rodig SJ; Chen HX; Wu CJ; Monjazeb AM; Hodi FS
Lancet Oncol; 2022 Feb; 23(2):279-291. PubMed ID: 35033226
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
Paz-Ares L; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Musso E; Havel L; Bondarenko I; Losonczy G; Conev N; Mann H; Dalvi TB; Jiang H; Goldman JW
ESMO Open; 2022 Apr; 7(2):100408. PubMed ID: 35279527
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
Ferris RL; Haddad R; Even C; Tahara M; Dvorkin M; Ciuleanu TE; Clement PM; Mesia R; Kutukova S; Zholudeva L; Daste A; Caballero-Daroqui J; Keam B; Vynnychenko I; Lafond C; Shetty J; Mann H; Fan J; Wildsmith S; Morsli N; Fayette J; Licitra L
Ann Oncol; 2020 Jul; 31(7):942-950. PubMed ID: 32294530
[TBL] [Abstract][Full Text] [Related]
12. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Garon EB; Cho BC; Luft A; Alatorre-Alexander J; Geater SL; Kim SW; Ursol G; Hussein M; Lim FL; Yang CT; Araujo LH; Saito H; Reinmuth N; Medic N; Mann H; Shi X; Peters S; Mok T; Johnson M
Lung Cancer; 2023 Dec; 186():107422. PubMed ID: 37992595
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study.
He JZ; Duval V; Jauslin P; Gonçalves A; Abegesah A; Fan C; Lim K; Song X; Chen C; Shi X; Mann H; Krug L; Ren S; Phipps A; Gibbs M; Zhou D
Clin Pharmacol Ther; 2023 Dec; 114(6):1375-1386. PubMed ID: 37777827
[TBL] [Abstract][Full Text] [Related]
15. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Psyrri A; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Vasilyev A; Karpenko A; Dvorkin M; Hsieh CY; Thungappa SC; Segura PP; Vynnychenko I; Haddad R; Kasper S; Mauz PS; Baker V; He P; Evans B; Wildsmith S; Olsson RF; Yovine A; Kurland JF; Morsli N; Seiwert TY;
Ann Oncol; 2023 Mar; 34(3):262-274. PubMed ID: 36535565
[TBL] [Abstract][Full Text] [Related]
16. NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer.
Cheng Y; Zhou Q; Han B; Fan Y; Shan L; Chang J; Sun S; Fang J; Chen Y; Sun J; Wu G; Mann H; Naicker K; Shire N; Mok T; de Castro G
Lung Cancer; 2023 Apr; 178():87-95. PubMed ID: 36806898
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
Garon EB; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; Robinet G; Le Moulec S; Natale R; Schneider J; Shepherd FA; Garassino MC; Geater SL; Szekely ZP; Van Ngoc T; Liu F; Scheuring U; Patel N; Peters S; Rizvi NA
Clin Lung Cancer; 2021 Jul; 22(4):301-312.e8. PubMed ID: 33775558
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07.
Kim M; Keam B; Ock CY; Kim SH; Kim YJ; Lim SM; Kim JS; Kim TM; Hong SH; Ahn MS; Shin SH; Kang EJ; Kim DW; Im SW; Kim JI; Lee JS; Kim JH; Heo DS
Thorac Cancer; 2020 Dec; 11(12):3482-3489. PubMed ID: 33026712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]